Media & Press relations

Our latest press releases

July 28, 2026

First-Half 2026 Results

bioMérieux's Q2 2026 sales totaled €981 million, with solid organic growth at +5%, reaching +7% excluding BIOFIRE® respiratory panels. The sales of the GO•28 growth drivers increased by 8.5% organically in Q2 26.

Discover more

Swipe for more

July 13, 2026

bioMérieux to Showcase Company’s Latest in Diagnostic Innovations at ADLM 2026

bioMérieux announced it will showcase its latest diagnostic solutions and innovations at the 2026 Association for Diagnostics & Laboratory Medicine (ADLM) Annual Conference & Clinical Lab Expo.

Read more
July 06, 2026

WATCHFIRE^™ Solution now available for wastewater monitoring in the United States through BioFire Defense

Salt Lake City, Utah, July 6, 2026 – bioMérieux, a world leader in the field of in vitro diagnostics, announces that the WATCHFIRE^™ Solution multiplex PCR test for wastewater monitoring is now available through BioFire Defense, a bioMérieux affiliate company. WATCHFIRE^™ offers two panel tests that screen for more than 40 pathogens that cause respiratory and gastrointestinal illnesses with easy near-source testing offering multiple PCR results in about an hour.

Read more
June 30, 2026

bioMérieux submits 510(k) to U.S. FDA for the latest versions of the BIOFIRE® FILMARRAY® Gastrointestinal Panels to enhance detection of gastrointestinal pathogens

bioMérieux, a world leader in the field of in vitro diagnostics, today announces the submission of the BIOFIRE® FILMARRAY® Gastrointestinal 1.1 (GI1.1) Panel and the BIOFIRE® FILMARRAY® Gastrointestinal 1.1 (GI1.1) Panel Mid to the U.S. Food and Drug Administration (FDA) for 510(k) review. These PCR* molecular panels test 22 and 11, respectively, of the most common bacteria, viruses, and parasites associated with gastroenteritis, all from one sample, with results available in approximately one hour.

Read more